ARTICLE IN PRESS

Arthroplasty Today xxx (2016) 1-5



Contents lists available at ScienceDirect

Arthroplasty Today

journal homepage: http://www.arthroplastytoday.org/

Original research

Do shorter lengths of stay increase readmissions after total joint replacements?

Udai S. Sibia, MD, MBA, Kip A. Waite, BA, Maura A. Callanan, MS, MBA, Adrian E. Park, MD, Paul J. King, MD, James H. MacDonald, MD *

Department of Surgery, Anne Arundel Medical Center, Annapolis, MD, USA

ARTICLE INFO

Article history: Received 22 March 2016 Received in revised form 3 May 2016 Accepted 5 May 2016 Available online xxx

Keywords: Enhanced recovery after surgery Complications Readmissions Total joint replacement Length of stay *Background:* Enhanced recovery after surgery protocols for total joint replacements (TJRs) emphasize early discharge, yet the impact on readmissions is not well documented. We evaluate the impact of a one-day length of stay (LOS) discharge protocol on readmissions.

Methods: We conducted a retrospective review of all primary TJRs (hip and knee) from April 2014 to March 2015. Patients who had adequate support to be discharged home were categorized into 2 groups, 1-day (n = 174) vs 2-day (n = 285) LOS groups. Patients discharged to rehabilitation were excluded (n = 196). *Results:* Patients in the 1 day group were more likely to be younger (61.7 vs 64.8 years, P < .001), be male (56.3% vs 40.4%, P = .001), and have a lower body mass index (30.0 vs 31.4 kg/m², P = .012). One-day LOS patients had shorter surgical times (79.7 vs 85.6 minutes, P = .001) and more likely had spinal anesthesia (46.0% vs 31.2%, P = .001). The overall 30-day all-cause (2.3% vs 2.5%, P = .591) and 90-day wound-related (1.1% vs 1.1%, P = .617) readmission rates were equivalent between groups.

Conclusions: Early discharge does not increase readmissions and may help attenuate costs associated with TJRs. Further refinement of protocols may allow for more patients to be safely discharged on postoperative day 1.

Copyright © 2016 The Authors. Published by Elsevier Inc. on behalf of American Association of Hip and Knee Surgeons. This is an open access article under the CC BY-NC-ND license (http://creativecommons. org/licenses/by-nc-nd/4.0/).

Introduction

Enhanced recovery after surgery (ERAS) programs expedite postoperative recovery, support an early discharge, and decrease postoperative complications by promoting a multidisciplinary approach to patient care [1]. Originally developed for colon surgery, ERAS pathways are being adopted across a range of surgical specialties [2–4]. Developed using evidence-based medicine, ERAS emphasizes a reduction in postoperative morbidity with strategies targeting anesthesia, analgesia, fluid management, nutrition, and postoperative ambulation [1]. Specifically for total joint replacements (TJRs), protocols include preoperative patient education and preparation, regional anesthesia, multimodal nonopioid pain management, aggressive postoperative fluid administration, and early mobilization [5–7].

* Corresponding author. Anne Arundel Medical Center, 2000 Medical Parkway, Belcher Pavilion Suite 101, Annapolis, MD 21401, USA. Tel.: +1 443 481 6699.

E-mail address: jmacdonald@osmc.net

According to the Centers for Disease Control and Prevention, there were 1.1 million TJRs performed in the United States in 2012, costing US \$18.75 billion [8]. By 2030, the demand for TJRs is projected to increase by 174% for primary total hip arthroplasties and 673% for primary total knee arthroplasties [9]. With two-thirds of all TJRs in the United States being performed on Medicare beneficiaries, these procedures represent a financial burden to the Centers for Medicare & Medicaid Services (CMS) [10,11]. Efforts to contain rising costs led to the creation of a bundled payments reimbursement model, which rewards hospitals and surgeons that can control costs. An important way to decrease costs is to decrease hospital length of stay (LOS).

ARTHROPLASTY TODAY

AAHKS

Early concerns have been raised that decreasing hospital stay may result in an increase in hospital readmissions; however, studies demonstrate that ERAS programs shorten LOS without increasing complications or readmissions [12–18]. In 2014, CMS updated its Readmissions Reduction Program to improve patient outcomes after TJRs [10]. These TJR-specific quality measures define 7-day, 30-day, and 90-day causes for readmissions [19]. Hospitals now incur a financial penalty for complications and readmissions associated with TIRs.

Rapid recovery and shorter lengths of stay have become an early measure of success after TJRs for both patients and hospitals.

http://dx.doi.org/10.1016/j.artd.2016.05.001

Please cite this article in press as: U.S. Sibia, et al., Do shorter lengths of stay increase readmissions after total joint replacements?, Arthroplasty Today (2016), http://dx.doi.org/10.1016/j.artd.2016.05.001

One or more of the authors of this paper have disclosed potential or pertinent conflicts of interest, which may include receipt of payment, either direct or indirect, institutional support, or association with an entity in the biomedical field which may be perceived to have potential conflict of interest with this work. For full disclosure statements refer to http://dx.doi.org/10.1016/j.artd.2016.05.001.

^{2352-3441/}Copyright © 2016 The Authors. Published by Elsevier Inc. on behalf of American Association of Hip and Knee Surgeons. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

2

With growing emphasis on cost efficiency, research efforts are now being directed at updating ERAS pathways to further shorten hospital stay, without adversely impacting patient outcomes [20–22]. The purpose of this study was to evaluate our readmissions rate after updating our institution's ERAS program to promote a 1-day LOS discharge protocol. The primary end point of this study was to quantify the overall all-cause 30-day readmissions rate. Secondary end points were to identify variables associated with a shorter LOS.

Material and methods

All TJRs at our institution were performed under our ERAS program. This includes preoperative, intraoperative, and postoperative protocols for care delivery. Preoperative measures were patient education, physical therapy, and medical evaluations. Patient education involved educational programs overviewing daily activities after surgery, identifying a specific care companion "Coach" at home, and discussing expectations. Preoperative physical therapy aimed to strengthen the upper and lower extremities. All patients had a medical evaluation within 30 days of surgery. Perioperative protocols included regional anesthesia, multimodal pain management, aggressive intraoperative fluid management, tranexamic acid utilization, anticoagulation prophylaxis, and day of surgery ambulation. Table 1 summarizes our pharmacological protocol. Standard Surgical Care Improvement Guidelines for perioperative antibiotics was followed. Pharmacologic (Aspirin 325 mg bid or Coumadin INR 1.8-2.4) and mechanical postoperative deep vein thrombosis prophylaxis was maintained in all patients. Oxycodone (5 mg increments as needed) was prescribed for pain unresponsive to nonopioid analgesics.

On April 1, 2014, our ERAS program was updated to promote an earlier (1 day LOS) discharge protocol. Specifically, patient education was updated to set expectations for discharge.

Table 1

Enhanced recovery after surgery pharmacological protocol.

Preoperative pain management (single dose within 2 h of incision) Acetaminophen 975 mg PO Lyrica 50 mg PO Protonix 40 mg PO Oxycontin 10 mg PO Scopolamine patch ^a Celebrex 200 mg PO ^b Tranexamic acid (TXA) Total knee replacement Preincision 10 mg/kg, maximum dose 1000 mg 3 h after incision 10 mg/kg, maximum dose 1000 mg Total hip replacement Preincision 10 mg/kg, maximum dose 1000 mg Periarticular injection Morphine 5 mg Toradol 15 mg ^a Ropivicaine 0.5% 30 cc Epinephrine 1/1000 0.3 cc Saline 30 cc Postoperative pain management Total knee replacement Acetaminophen 975 mg PO q 4 as needed Lyrica 50 mg PO gid \times 14 d Celebrex 200 mg PO qd \times 30 d Oxycodone 5 mg as needed Total hip replacement Acetaminophen 975 mg PO q 4 as needed Oxycodone 5 mg as needed Lyrica 50 mg PO bid \times 14 d ^c		-
Acetaminophen 975 mg PO Lyrica 50 mg PO Protonix 40 mg PO Oxycontin 10 mg PO Scopolamine patch ^a Celebrex 200 mg PO ^b Tranexamic acid (TXA) Total knee replacement Preincision 10 mg/kg, maximum dose 1000 mg 3 h after incision 10 mg/kg, maximum dose 1000 mg Total hip replacement Preincision 10 mg/kg, maximum dose 1000 mg Periarticular injection Morphine 5 mg Toradol 15 mg ^a Ropivicaine 0.5% 30 cc Epinephrine 1/1000 0.3 cc Saline 30 cc Postoperative pain management Total knee replacement Acetaminophen 975 mg PO q 4 as needed Lyrica 50 mg PO gd \times 30 d Oxycodone 5 mg as needed Total hip replacement Acetaminophen 975 mg PO q 4 as needed Oxycodone 5 mg as needed Lyrica 50 mg PO bid \times 14 d ^c	Preoperative pain management (single dose within 2 h of incision)	
Lyrica 50 mg PO Protonix 40 mg PO Oxycontin 10 mg PO Scopolamine patch ^a Celebrex 200 mg PO ^b Tranexamic acid (TXA) Total knee replacement Preincision 10 mg/kg, maximum dose 1000 mg 3 h after incision 10 mg/kg, maximum dose 1000 mg Total hip replacement Preincision 10 mg/kg, maximum dose 1000 mg Periarticular injection Morphine 5 mg Toradol 15 mg ^a Ropivicaine 0.5% 30 cc Epinephrine 1/1000 0.3 cc Saline 30 cc Postoperative pain management Total knee replacement Acetaminophen 975 mg PO q 4 as needed Lyrica 50 mg PO pid × 14 d Celebrex 200 mg PO qd × 30 d Oxycodone 5 mg as needed Total hip replacement Acetaminophen 975 mg PO q 4 as needed Uyrica 50 mg PO bid × 14 d ^c	Acetaminophen 975 mg PO	
Protonix 40 mg PO Oxycontin 10 mg PO Scopolamine patch ^a Celebrex 200 mg PO ^b Tranexamic acid (TXA) Total knee replacement Preincision 10 mg/kg, maximum dose 1000 mg 3 h after incision 10 mg/kg, maximum dose 1000 mg Total hip replacement Preincision 10 mg/kg, maximum dose 1000 mg Periarticular injection Morphine 5 mg Toradol 15 mg ^a Ropivicaine 0.5% 30 cc Epinephrine 1/1000 0.3 cc Saline 30 cc Postoperative pain management Total knee replacement Acetaminophen 975 mg PO q 4 as needed Lyrica 50 mg PO bid × 14 d Celebrex 200 mg PO qd × 30 d Oxycodone 5 mg as needed Lyrica 50 mg PO bid × 14 d ^c	Lyrica 50 mg PO	
Oxycontin 10 mg PO Scopolamine patch ^a Celebrex 200 mg PO ^b Tranexamic acid (TXA) Total knee replacement Preincision 10 mg/kg, maximum dose 1000 mg 3 h after incision 10 mg/kg, maximum dose 1000 mg Total hip replacement Preincision 10 mg/kg, maximum dose 1000 mg Periarticular injection Morphine 5 mg Toradol 15 mg ^a Ropivicaine 0.5% 30 cc Epinephrine 1/1000 0.3 cc Saline 30 cc Postoperative pain management Total knee replacement Acetaminophen 975 mg PO q 4 as needed Lyrica 50 mg PO bid \times 14 d Celebrex 200 mg PO qd \times 30 d Oxycodone 5 mg as needed Lyrica 50 mg PO bid \times 14 d ^c	Protonix 40 mg PO	
Scopolamine patch ^a Celebrex 200 mg PO ^b Tranexamic acid (TXA) Total knee replacement Preincision 10 mg/kg, maximum dose 1000 mg 3 h after incision 10 mg/kg, maximum dose 1000 mg Total hip replacement Preincision 10 mg/kg, maximum dose 1000 mg Periarticular injection Morphine 5 mg Toradol 15 mg ^a Ropivicaine 0.5% 30 cc Epinephrine 1/1000 0.3 cc Saline 30 cc Postoperative pain management Total knee replacement Acetaminophen 975 mg PO q 4 as needed Lyrica 50 mg PO gid \times 14 d Celebrex 200 mg PO qid \times 30 d Oxycodone 5 mg as needed Total hip replacement Acetaminophen 975 mg PO q 4 as needed Cycycodone 5 mg as needed Dyrica 50 mg PO gid \times 14 d ^c	Oxycontin 10 mg PO	
Celebrex 200 mg PO ⁶ Tranexamic acid (TXA) Total knee replacement Preincision 10 mg/kg, maximum dose 1000 mg 3 h after incision 10 mg/kg, maximum dose 1000 mg Total hip replacement Preincision 10 mg/kg, maximum dose 1000 mg Periarticular injection Morphine 5 mg Toradol 15 mg ⁴ Ropivicaine 0.5% 30 cc Epinephrine 1/1000 0.3 cc Saline 30 cc Postoperative pain management Total knee replacement Acetaminophen 975 mg PO q 4 as needed Lyrica 50 mg PO bid \times 14 d Celebrex 200 mg PO qd \times 30 d Oxycodone 5 mg as needed Total hip replacement Acetaminophen 975 mg PO q 4 as needed Total hip replacement Acetaminophen 975 mg PO q 4 as needed Total hip replacement Acetaminophen 975 mg PO q 4 as needed Total hip replacement Acetaminophen 975 mg PO q 4 as needed Total hip replacement Acetaminophen 975 mg PO q 4 as needed Oxycodone 5 mg as needed Lyrica 50 mg PO bid \times 14 d ^c	Scopolamine patch ^a	
Tranexamic acid (TXA) Total knee replacement Preincision 10 mg/kg, maximum dose 1000 mg 3 h after incision 10 mg/kg, maximum dose 1000 mg Total hip replacement Preincision 10 mg/kg, maximum dose 1000 mg Periarticular injection Morphine 5 mg Toradol 15 mg ⁴ Ropivicaine 0.5% 30 cc Epinephrine 1/1000 0.3 cc Saline 30 cc Postoperative pain management Total knee replacement Acetaminophen 975 mg PO q 4 as needed Lyrica 50 mg PO bid × 14 d Celebrex 200 mg PO qd × 30 d Oxycodone 5 mg as needed Lyrica 50 mg PO bid × 14 d ^c	Celebrex 200 mg PO ^b	
Total knee replacement Preincision 10 mg/kg, maximum dose 1000 mg 3 h after incision 10 mg/kg, maximum dose 1000 mg Total hip replacement Preincision 10 mg/kg, maximum dose 1000 mg Periarticular injection Morphine 5 mg Toradol 15 mg ⁴ Ropivicaine 0.5% 30 cc Epinephrine 1/1000 0.3 cc Saline 30 cc Postoperative pain management Total knee replacement Acetaminophen 975 mg PO q 4 as needed Lyrica 50 mg PO bid \times 14 d Celebrex 200 mg PO qd \times 30 d Oxycodone 5 mg as needed Total hip replacement Acetaminophen 975 mg PO q 4 as needed Oxycodone 5 mg as needed Lyrica 50 mg PO bid \times 14 d ^c	Tranexamic acid (TXA)	
Preincision 10 mg/kg, maximum dose 1000 mg 3 h after incision 10 mg/kg, maximum dose 1000 mg Total hip replacement Preincision 10 mg/kg, maximum dose 1000 mg Periarticular injection Morphine 5 mg Toradol 15 mg ⁴ Ropivicaine 0.5% 30 cc Epinephrine 1/1000 0.3 cc Saline 30 cc Postoperative pain management Total knee replacement Acetaminophen 975 mg PO q 4 as needed Lyrica 50 mg PO bid × 14 d Celebrex 200 mg PO qd × 30 d Oxycodone 5 mg as needed Total hip replacement Acetaminophen 975 mg PO q 4 as needed Oxycodone 5 mg as needed Lyrica 50 mg PO bid × 14 d ^c	Total knee replacement	
3 h after incision 10 mg/kg, maximum dose 1000 mg Total hip replacement Preincision 10 mg/kg, maximum dose 1000 mg Periarticular injection Morphine 5 mg Toradol 15 mg ⁴ Ropivicaine 0.5% 30 cc Epinephrine 1/1000 0.3 cc Saline 30 cc Postoperative pain management Total knee replacement Acetaminophen 975 mg PO q 4 as needed Lyrica 50 mg PO bid × 14 d Celebrex 200 mg PO qd × 30 d Oxycodone 5 mg as needed Total hip replacement Acetaminophen 975 mg PO q 4 as needed Unit preplacement Acetaminophen 975 mg PO q 4 as needed Total hip replacement Acetaminophen 975 mg PO q 4 as needed Total hip replacement Acetaminophen 975 mg PO q 4 as needed Oxycodone 5 mg as needed Lyrica 50 mg PO bid × 14 d ^c	Preincision 10 mg/kg, maximum dose 1000 mg	
Total hip replacement Preincision 10 mg/kg, maximum dose 1000 mg Periarticular injection Morphine 5 mg Toradol 15 mg ³ Ropivicaine 0.5% 30 cc Epinephrine 1/1000 0.3 cc Saline 30 cc Postoperative pain management Total knee replacement Acetaminophen 975 mg PO q 4 as needed Lyrica 50 mg PO bid \times 14 d Celebrex 200 mg PO qd \times 30 d Oxycodone 5 mg as needed Total hip replacement Acetaminophen 975 mg PO q 4 as needed Total hip replacement Acetaminophen 975 mg PO q 4 as needed Total hip replacement Acetaminophen 975 mg PO q 4 as needed Dyrica 50 mg PO bid \times 14 d ^c	3 h after incision 10 mg/kg, maximum dose 1000 mg	
Preincision 10 mg/kg, maximum dose 1000 mg Periarticular injection Morphine 5 mg Toradol 15 mg ⁴ Ropivicaine 0.5% 30 cc Epinephrine 1/1000 0.3 cc Saline 30 cc Postoperative pain management Total knee replacement Acetaminophen 975 mg PO q 4 as needed Lyrica 50 mg PO bid × 14 d Celebrex 200 mg PO qd × 30 d Oxycodone 5 mg as needed Total hip replacement Acetaminophen 975 mg PO q 4 as needed Oxycodone 5 mg as needed Lyrica 50 mg PO bid × 14 d ^c	Total hip replacement	
Periarticular injection Morphine 5 mg Toradol 15 mg ^a Ropivicaine 0.5% 30 cc Epinephrine 1/1000 0.3 cc Saline 30 cc Postoperative pain management Total knee replacement Acetaminophen 975 mg PO q 4 as needed Lyrica 50 mg PO bid × 14 d Celebrex 200 mg PO qd × 30 d Oxycodone 5 mg as needed Total hip replacement Acetaminophen 975 mg PO q 4 as needed Oxycodone 5 mg as needed Lyrica 50 mg PO bid × 14 d ^c	Preincision 10 mg/kg, maximum dose 1000 mg	
Morphine 5 mg Toradol 15 mg ³ Ropivicaine 0.5% 30 cc Epinephrine 1/1000 0.3 cc Saline 30 cc Postoperative pain management Total knee replacement Acetaminophen 975 mg PO q 4 as needed Lyrica 50 mg PO bid × 14 d Celebrex 200 mg PO qd × 30 d Oxycodone 5 mg as needed Total hip replacement Acetaminophen 975 mg PO q 4 as needed Oxycodone 5 mg as needed Lyrica 50 mg PO bid × 14 d ^c	Periarticular injection	
Toradol 15 mg ^a Ropivicaine 0.5% 30 cc Epinephrine 1/1000 0.3 cc Saline 30 cc Postoperative pain management Total knee replacement Acetaminophen 975 mg PO q 4 as needed Lyrica 50 mg PO bid × 14 d Celebrex 200 mg PO qd × 30 d Oxycodone 5 mg as needed Total hip replacement Acetaminophen 975 mg PO q 4 as needed Oxycodone 5 mg as needed Lyrica 50 mg PO bid × 14 d ^c	Morphine 5 mg	
Ropivicaine 0.5% 30 cc Epinephrine 1/1000 0.3 cc Saline 30 cc Postoperative pain management Total knee replacement Acetaminophen 975 mg PO q 4 as needed Lyrica 50 mg PO bid × 14 d Celebrex 200 mg PO qd × 30 d Oxycodone 5 mg as needed Total hip replacement Acetaminophen 975 mg PO q 4 as needed Oxycodone 5 mg as needed Lyrica 50 mg PO bid × 14 d ^c	Toradol 15 mg ^a	
Epinephrine 1/1000 0.3 cc Saline 30 cc Postoperative pain management Total knee replacement Acetaminophen 975 mg PO q 4 as needed Lyrica 50 mg PO bid × 14 d Celebrex 200 mg PO qd × 30 d Oxycodone 5 mg as needed Total hip replacement Acetaminophen 975 mg PO q 4 as needed Oxycodone 5 mg as needed Lyrica 50 mg PO bid × 14 d ^c	Ropivicaine 0.5% 30 cc	
Saline 30 cc Postoperative pain management Total knee replacement Acetaminophen 975 mg PO q 4 as needed Lyrica 50 mg PO bid \times 14 d Celebrex 200 mg PO qd \times 30 d Oxycodone 5 mg as needed Total hip replacement Acetaminophen 975 mg PO q 4 as needed Oxycodone 5 mg as needed Lyrica 50 mg PO bid \times 14 d ^c	Epinephrine 1/1000 0.3 cc	
Postoperative pain management Total knee replacement Acetaminophen 975 mg PO q 4 as needed Lyrica 50 mg PO bid \times 14 d Celebrex 200 mg PO qd \times 30 d Oxycodone 5 mg as needed Total hip replacement Acetaminophen 975 mg PO q 4 as needed Oxycodone 5 mg as needed Lyrica 50 mg PO bid \times 14 d ^c	Saline 30 cc	
Total knee replacement Acetaminophen 975 mg PO q 4 as needed Lyrica 50 mg PO bid \times 14 d Celebrex 200 mg PO qd \times 30 d Oxycodone 5 mg as needed Total hip replacement Acetaminophen 975 mg PO q 4 as needed Oxycodone 5 mg as needed Lyrica 50 mg PO bid \times 14 d ^c	Postoperative pain management	
Acetaminophen 975 mg PO q 4 as needed Lyrica 50 mg PO bid \times 14 d Celebrex 200 mg PO qd \times 30 d Oxycodone 5 mg as needed Total hip replacement Acetaminophen 975 mg PO q 4 as needed Oxycodone 5 mg as needed Lyrica 50 mg PO bid \times 14 d ^c	Total knee replacement	
Lyrica 50 mg PO bid \times 14 d Celebrex 200 mg PO qd \times 30 d Oxycodone 5 mg as needed Total hip replacement Acetaminophen 975 mg PO q 4 as needed Oxycodone 5 mg as needed Lyrica 50 mg PO bid \times 14 d ^c	Acetaminophen 975 mg PO q 4 as needed	
Celebrex 200 mg PO qd \times 30 d Oxycodone 5 mg as needed Total hip replacement Acetaminophen 975 mg PO q 4 as needed Oxycodone 5 mg as needed Lyrica 50 mg PO bid \times 14 d ^c	Lyrica 50 mg PO bid \times 14 d	
Oxycodone 5 mg as needed Total hip replacement Acetaminophen 975 mg PO q 4 as needed Oxycodone 5 mg as needed Lyrica 50 mg PO bid × 14 d ^c	Celebrex 200 mg PO qd \times 30 d	
Total hip replacement Acetaminophen 975 mg PO q 4 as needed Oxycodone 5 mg as needed Lyrica 50 mg PO bid × 14 d ^c	Oxycodone 5 mg as needed	
Acetaminophen 975 mg PO q 4 as needed Oxycodone 5 mg as needed Lyrica 50 mg PO bid \times 14 d ^c	Total hip replacement	
Oxycodone 5 mg as needed Lyrica 50 mg PO bid \times 14 d ^c	Acetaminophen 975 mg PO q 4 as needed	
Lyrica 50 mg PO bid \times 14 d ^c	Oxycodone 5 mg as needed	
	Lyrica 50 mg PO bid \times 14 d ^c	

PO, per oral.

^a Unless contraindicated.

^b Not given if periarticular injection included Toradol 15 cc.

^c In select patients with breakthrough pain.

Perioperative modifications included the increased use of regional anesthesia. The use of femoral nerve blocks for TKRs was discontinued. Patient-controlled anesthesia was discontinued. Day of surgery mobilization was attempted in almost all patients. Acetaminophen (975 mg) was added to the postoperative analgesic medication list.

Study design

Institutional review board approval was obtained. A prospectively maintained institutional Joint Outcomes database was queried for all primary total hip and knee replacements. All procedures were performed by 2 surgeons from April 2014 to March 2015. The 2 surgical techniques used for THRs were the direct anterior and posterior-lateral approach. There was no criterion for assigning patients to a particular surgical technique. It was determined using patient and surgeon preference. All TKRs were performed via a standard medial patellar arthrotomy. The new 1-day LOS protocol was introduced on April 1, 2014. The aim of this study was to evaluate the impact of an earlier (1-day LOS) discharge on readmissions.

A total of 655 TJRs met our initial criteria, of which 196 were discharged to rehabilitation and excluded. This exclusion criterion was based on Medicare's requirement for a minimum 3-day inpatient stay for patients to go to a skilled nursing facility. This left a total of 459 (70%) TJRs in this study. Patients were then categorized into the 1-day or 2-day LOS groups. Length of hospital stay was determined by medical clearance and the ability to safely ambulate after surgery.

Patient demographics of age, gender, body mass index (BMI), and comorbidity were recorded. Table 2 summarizes the patient demographics for patients discharged to rehabilitation facilities that were excluded (LOS \geq 3 days) from this study. The primary end points were our readmissions rate, which were assessed using CMS's TJR-specific quality measures [19]. Secondary end points examined variables associated with early discharge.

CMS TJR-specific quality measures: patients were evaluated for a total of 8 postoperative complications [19]. Patients presenting with an acute myocardial infarct, pneumonia, or sepsis/septicemia/ shock during the index of admission or within 7 days of admission

Table 2

Patient demographics for patients excluded from study.

Demographics	$\text{LOS} \geq 3 \text{ d}$
Ν	196
Age (y)	70.4
Body mass index (kg/m ²)	31.2
Gender	
Male	28.6%
Female	71.4%
Comorbidity	
Diabetes	25.0%
Hypertension	74.0%
Hyperlipidemia	57.7%
Gastroesophageal reflux disease	42.3%
Coronary artery disease	12.2%
Chronic obstructive pulmonary disease	11.7%
Congestive heart failure	4.6%
Liver cirrhosis	0.5%
Atrial fibrillation	14.3%
Pacemakers	1.5%
Past medical history	
History of DVT/PE	5.6%
History of CVA/TIA	8.2%
History of myocardial infarct	4.1%

CVA, cerebrovascular accident; DVT, deep vein thrombosis; PE, pulmonary embolism; TIA, transient ischemic attack.

Please cite this article in press as: U.S. Sibia, et al., Do shorter lengths of stay increase readmissions after total joint replacements?, Arthroplasty Today (2016), http://dx.doi.org/10.1016/j.artd.2016.05.001

Download English Version:

https://daneshyari.com/en/article/8796155

Download Persian Version:

https://daneshyari.com/article/8796155

Daneshyari.com